Atomo Diagnostics logo

AT1 - Atomo Diagnostics Share Price

A$0.315 0.0  0.0%

Last Trade - 03/06/20

Small Cap
Market Cap £97.1m
Enterprise Value £103.4m
Revenue £776k
Position in Universe 518th / 1838
Unlock AT1 Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 31 December 2019, Atomo Diagnostics Ltd revenues increased from A$65K to A$937K. Net loss increased 6% to A$2.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest Expense increase from A$519K to A$2.3M (expense), Government Grants received decrease from A$391K (income) to A$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AT1 Revenue Unlock AT1 Revenue

Net Income

AT1 Net Income Unlock AT1 Revenue

Normalised EPS

AT1 Normalised EPS Unlock AT1 Revenue

PE Ratio Range

AT1 PE Ratio Range Unlock AT1 Revenue

Dividend Yield Range

AT1 Dividend Yield Range Unlock AT1 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AT1 EPS Forecasts Unlock AT1 Revenue
Profile Summary

Atomo Diagnostics Ltd is an Australia-based medical device company. The Company is focused on developing its test device technologies that enables blood-based medical diagnostic testing processes. It provides point of care devices for rapid diagnostic testing (RDT). Its AtomoRapid RDT platforms are customizable for a variety of blood-based lateral flow test assays and are used for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its RTD device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. It also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display.

Last Annual June 30th, 2019
Last Interim December 31st, 2019
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange Australian Stock Exchange - SEATS
Shares in Issue 560,901,359
Free Float (0.0%)
Eligible for
AT1 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AT1
Upcoming Events for AT1
Frequently Asked Questions for Atomo Diagnostics
What is the Atomo Diagnostics share price?

As of 03/06/20, shares in Atomo Diagnostics are trading at A$0.315, giving the company a market capitalisation of £97.1m. This share price information is delayed by 15 minutes.

How has the Atomo Diagnostics share price performed this year?

Shares in Atomo Diagnostics are currently trading at A$0.315 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atomo Diagnostics price has moved by % over the past year.

What are the analyst and broker recommendations for Atomo Diagnostics?

There are no analysts currently covering Atomo Diagnostics.

When will Atomo Diagnostics next release its financial results?

Atomo Diagnostics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Atomo Diagnostics dividend yield?

Atomo Diagnostics does not currently pay a dividend.

Does Atomo Diagnostics pay a dividend?

Atomo Diagnostics does not currently pay a dividend.

When does Atomo Diagnostics next pay dividends?

Atomo Diagnostics does not currently pay a dividend.

How do I buy Atomo Diagnostics shares?

To buy shares in Atomo Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Atomo Diagnostics?

Shares in Atomo Diagnostics are currently trading at A$0.315, giving the company a market capitalisation of £97.1m.

Where are Atomo Diagnostics shares listed? Where are Atomo Diagnostics shares listed?

Here are the trading details for Atomo Diagnostics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: AT1
What kind of share is Atomo Diagnostics?

Based on an overall assessment of its quality, value and momentum, Atomo Diagnostics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Atomo Diagnostics share price forecast 2020?

We were not able to load any forecast data for Atomo Diagnostics.

How can I tell whether the Atomo Diagnostics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atomo Diagnostics. Over the past six months, the relative strength of its shares against the market has been %. At the current price of A$0.315, shares in Atomo Diagnostics are trading at -21.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Atomo Diagnostics PE Ratio?

We were not able to find PE ratio data for Atomo Diagnostics.

Who are the key directors of Atomo Diagnostics?

Atomo Diagnostics's management team is headed by:

John Kelly - CEO
Byron Darroch - GMG
Hans Fredman - OTH
Robert Snoch - OTH
Who are the major shareholders of Atomo Diagnostics?

Here are the top five shareholders of Atomo Diagnostics based on the size of their shareholding:

Dalraida Holdings Pty. Ltd. Corporation
Percentage owned: 11.79% (66.2m shares)
Global Health Investment Fund I, LLC Corporation
Percentage owned: 11.38% (63.9m shares)
Walker Group Holdings Pty. Ltd. Corporation
Percentage owned: 8.32% (46.7m shares)
Perennial Value Management Ltd. Investment Advisor
Percentage owned: 6.42% (36.0m shares)
Ellerston Capital Limited Investment Advisor/Hedge Fund
Percentage owned: 6.13% (34.4m shares)
Similar to AT1
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.